Mounjaro is a dual GIP/GLP1 receptor agonist, while Ozempic is a GLP1 receptor agonist, which partly explains differences in their effects
Debated Unsettled Safety Issues Cancer Concerns about a possible connection between GLP-1 RAs and the development of neoplasms have spurred several investigations, especially on thyroid and pancreatic cancers due to a plausible mechanism and a large number of reports in the post-marketing phase [118, 128, 130]
If you are taking Zepbound along with sulfonylureas or insulins, you may need to adjust the dose of these medications to help avoid low blood sugar levels
Always consult with your healthcare provider for personalized guidance on traveling with medications
The total weight loss at 12 months for most people falls between 15 and 22% of starting body weight
What the FDAs New Ruling on Compounded Semaglutide Means for You You may have seen headlines about a new FDA ruling on compounded semaglutide, and you might be wondering what it means for your treatment